Condition
Triple-Negative Breast Neoplasm
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Active Not Recruiting1
Not Yet Recruiting1
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07011823Phase 2Not Yet RecruitingPrimary
Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC
NCT03077776Not ApplicableActive Not RecruitingPrimary
Tracking Triple-negative Breast Cancer Evolution Through Therapy
NCT02685306Phase 2Withdrawn
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Showing all 3 trials